侯雲龍，男，現任以嶺醫藥研究院新藥評價中心副院長兼藥理部主任，世界中醫藥學會聯合會抗衰老專委會秘書長。
基本介紹
- 中文名：侯雲龍
- 國籍：中國
- 職務：以嶺醫藥研究院新藥評價中心副院長兼藥理部主任、世界中醫藥學會聯合會抗衰老專業委員會秘書長
所獲榮譽,社會活動,新聞採訪,代表作品,
所獲榮譽
2021年，侯雲龍獲得河北省科學技術獎一等獎。
社會活動
2023年2月25日， 侯雲龍教授參加第十九屆國際絡病學大會並做主題報告。
新聞採訪
2023年5月14日，世界中醫藥學會聯合會抗衰老專委會秘書長侯雲龍做客新華社會客廳並接受採訪。
2023年05月24日，侯雲龍教授參加2023中國健康促進與健康產業高質量發展論壇，並接受新華日報健康欄目專訪。
代表作品
• Shensong Yangxin Capsule Reduces the Susceptibility of Arrhythmia in db/db Mice via Inhibiting the Inflammatory Response Induced by Endothelium Dysfunction. Drug Des Devel Ther. 2023 Feb 5;17:313-330.
• Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects. Phytomedicine. 2023 Apr;112:154688.
• Dual targets of lethal apoptosis and protective autophagy in liver cancer with periplocymarin elicit a limited therapeutic effect. Int J Oncol. 2023 Mar;62(3):44.
• Huogu injection alleviates SONFH by regulating adipogenic differentiation of BMSCs via targeting the miR-34c-5p/MDM4 pathway. Gene. 2022 Sep 5;838:146705.
• Altered gut microbiota and metabolites profile are associated with reduced bone metabolism in ethanol-induced osteoporosis. Cell Prolif. 2022 Jul;55(7):e13245.
• Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. Pharm Biol. 2022 Dec;60(1):274-281.
• The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2). Chin Med. 2021 Oct 18;16(1):104.
• Analysis of Resibufogenin on Cardiac conduction reveals a species difference in the cardiac electrophysiology: Rats versus guinea pigs. Biomed Pharmacother. 2021 Jul;139:111581.
• Comparison of exosomes derived from induced pluripotent stem cells and mesenchymal stem cells as therapeutic nanoparticles for treatment of corneal epithelial defects. Aging (Albany NY). 2020 Oct 13;12(19):19546-19562.
• Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020 Jun;156:104761.
